Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Join us in London, 16-18 October, to discover the latest advancements in precision oncology, genomic sequencing, biomarker discovery, the use of AI for drug development and precision medicine, and more
Shape the future of cancer drug development and be part of this unique forum gathering key actors in the field
A unique opportunity to explore the ESMO Guidelines in the context of real-world cases and have your questions answered during the live Q&A
Keep up to date with practice-changing publications in non-small-cell lung cancer and advanced urothelial cancer by joining this in-depth analysis with leading experts
Listen to lectures on early relapses, future directions with ADCs, ongoing research in immunotherapy and join the live discussion with the speakers’ panel
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
However, the future of TKI combinations for these rare tumours is uncertain
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest
Several studies report on promising data with immunomodulation and alternative approaches
However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
Evidence for efficacy is based on the results from the KEYNOTE-483 study
Evidence for efficacy is based on the results from the AEGEAN study
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
However, the future of TKI combinations for these rare tumours is uncertain
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest
Evidence for efficacy is based on the results from the KEYNOTE-483 study
Evidence for efficacy is based on the results from the AEGEAN study
Findings from the TROPHY-U-01 Cohort 2 study
Fundings from the LMS04 study
Evidence for efficacy is based on the results from the PERSEUS study
Findings from the IMADGIST study
Findings from extended follow-up of the DeLLphi-300 study
Evidence for efficacy is based on the results from the MARIPOSA study
Findings from the ProBio study
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Portugal
Portugal
Republic of Singapore
United Kingdom
Spain
France
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
